Andrea Aguayo, PharmD

Previous studies have shown that individuals living with HIV are at higher risk for heart disease than individuals without HIV

A notable revision now includes a dual GIP and GLP-1 receptor agonist (tirzepatide) as an additional option for glycemic management, preferred over insulin.

This latest revision introduces a new set of drug criteria, refines the existing ones, and enhances the overall formatting to ensure increased ease of use and clarity for its recommendations.